TTP399

TTP399 is an investigational new drug being developed by vTv Therapeutics for the treatment of type 1 diabetes. It is an orally administered, liver-selective glucokinase activator.

Mechanism of Action

TTP399 works by activating glucokinase, a key regulatory enzyme in the liver that plays a significant role in glucose metabolism. When glucose levels are high, glucokinase converts glucose to glucose-6-phosphate, which is then used to produce energy or stored as glycogen. By activating glucokinase, TTP399 increases the rate of glucose metabolism, thereby reducing blood glucose levels.

Clinical Trials

TTP399 has undergone several clinical trials to evaluate its safety and efficacy in patients with type 1 diabetes. In a Phase 2 trial, TTP399 demonstrated a statistically significant reduction in HbA1c levels, a key marker of long-term blood glucose control, compared to placebo. The drug was also well-tolerated, with no reports of severe hypoglycemia or diabetic ketoacidosis.

Potential Benefits

TTP399 could potentially offer several benefits over existing treatments for type 1 diabetes. As an oral medication, it would be more convenient than injectable insulin. Furthermore, its liver-selectivity could reduce the risk of hypoglycemia, a common side effect of many diabetes medications.

Future Development

vTv Therapeutics is currently planning further clinical trials to confirm the efficacy and safety of TTP399 in a larger population of patients with type 1 diabetes.

File:TTP399 structure.png

Chemical structure of TTP399

See Also

• Glucokinase
• Type 1 diabetes
• vTv Therapeutics
• Clinical trial